Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Avm Biotechnology LLC has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 2 distinct art units, indicating multiple examiner assignments within a more concentrated unit structure. Counsel should preserve separate examiner-level tracking while coordinating technical positions for matters sharing an art-unit environment.
HAVLIN, ROBERT H is the busiest examiner, with 1 pending matter. The examiner figure is below the portfolio total, so the pending activity is distributed among the identified examiners. A unified biotechnology strategy may support consistency, but each response should remain tied to its examiner and applicable art-unit record.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
| SANG, HONG | 1 | 54.9% | +62.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | SANG, HONG | 14d |
| 17801293 | Lymphocyte Population and Methods for Producing Same | CHICKS, ASHLI ARIANA | 27d |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 1626 | §103§112Other | Final Rejection | 23d overdue | Pending | Oct 25, 2022 |
| 17801293 | Lymphocyte Population and Methods for Producing Same | CHICKS, ASHLI ARIANA | 1626 | §103Other | Final Rejection | 27d | Pending | Aug 22, 2022 |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | SANG, HONG | 1646 | §112 | Final Rejection | 14d | Pending | Dec 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvm Biotechnology LLC has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Robert H Havlin has the most, with 1 of Avm Biotechnology LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
